Dr Sundar has published extensively and is very active in clinical research and clinical trials.

1 S Sundar, P Symonds. Cancer patients’ anxiety. The Lancet. 2003. 361: 1746 – 47.
2 S Sundar, P Lawton. International register of trial acronyms. The Lancet. 2004. 363:171
3 S Sundar, MP Decatris, DM Kumar. Cure without complications: A population based analysis of treatment intensity and survival in testicular Germ Cell tumours. Clinical Oncology. 2003. Vol 15 (2): 84-85.
4 RA Sharma, MP Decatris, Sundar Santhanam, R Roy, AE Osman, CB Clarke, S Khanna, KJ O’Byrne . Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol. 2003;52(5):367-70.
5 S Sundar, P Symonds, C Deehan. The Tolerance of Pelvic organs to Radiation treatment for Carcinoma of Cervix. Clinical Oncology. 2003.15(5):240-7
6 S Sundar, RP Symonds. Diagnostic Radiology for Radiotherapist: The case for structured training in cross-sectional imaging (CT and MRI). Clinical Oncology. 2002. Vol 14 (5): 413-414
7 Sundar Santhanam, KJ O’Byrne. Antioestrogens and breast cancer. Journal of the British Menopause Society.2001: Vol 7(1): 21-26
8 S Sundar, M Decatris, KJ O’ Byrne. Management of endocrine resistant breast cancer. Journal of the British Menopause Society.2004 Mar;10(1):16-23.
9 S Sundar, SY Chan. Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel. Anti-Cancer Drugs.2003.14 (4): 327
10 Sundar Santhanam, M Decatris, KJ O’ Byrne. Potential of Interferon-alpha in Solid Tumours: Part-2. BioDrugs. 2002, Vol. 16(5):349-72.
11 M Decatris, Sundar Santhanam, KJ O’ Byrne. Potential of Interferon-alpha  in Solid Tumours: Part-1. BioDrugs. 2002, Vol. 16, (4): 261-281.
12 M Decatris, S Sundar, KJ O’ Byrne. Platinum based Chemotherapy in metastatic breast cancer: Current Status. Cancer Treat Rev. 2004;30(1):53-81
13 KJ O’ Byrne, S Sundar. Role of anthracyclines in Ovarian cancer. MIMS Advances: Ovarian cancer. 2003. May. 5-6.
14 DM Kumar, S Sundar, S Vasanthan. A Case of Paclitaxel induced Pancreatitis. Clinical Oncology. 2003. Vol 15 (1):35
15 Muthu Kumar D, Symonds RP, Sundar S, Ibrahim K, Savelyich BS, Miller E.  Information needs of Asian and White British cancer patients and their families in Leicestershire: a cross-sectional survey. Br J Cancer. 2004 Apr 19;90(8):1474-8.
16 S Sundar, RP Symonds, MP Decartis, DM Kumar, A Osman, S Vasanthan,KJ O’Byrne. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum based therapy. Gynecologic Oncology.2004; 94(2):502-8.
17 M.P. Decatris, S. Sundar and K.J. O’Byrne. Platinum-based Chemotherapy in Metastatic Breast Cancer: The Leicester (UK) Experience. Clinical Oncology. 2005: Vol 17 (4): 249-257
18 S.Sundar, P Symonds, C Deehan. Radiotherapy to patients with artificial cardiac pacemakers (pdf full text copy). Cancer Treat Rev. 2005;31(6):474-86.
19 S.Sundar, K.J. O’Byrne. CA-125 criteria for response evaluation in Ovarian Cancer. Gynecol Oncol. 2005;98(3):520-1.
20 A Dhadda, D Lakshmanan, M Sokal, S Sundar . Age does not influence acute toxicity during radiotherapy dose escalation for prostate cancer. Clin Oncol (R Coll Radiol). 2006 Aug;18(6):506-7.
21 M. Griffin, A. Dhadda, A. Wade, M. Sokal, S. Sundar. Male Cancer Patients’ Attitudes towards Female Health Professionals during Urological Consultations. Clin Oncol (R Coll Radiol). 2006 Sep;18(7):572-3.
22 Smellie WS, Forth J, Sundar S, Kalu E, McNulty CA, Sherriff E, Watson ID, Croucher C, Reynolds TM, Carey PJ. Best Practice in Primary Care Pathology: review 4. Should PSA should be measured in asymptomatic men?. What action should be taken in a patient with a raised PSA?. How often PSA should be measured in patients who have been diagnosed as suffering from prostate cancer?. J Clin Pathol. 2006 Sep;59(9):893-902.
23 Chaudhuri A, Griffin M, Sundar S. Utility of regular serum biochemistry and midstream urine cultures in men undergoing three-dimensional conformal pelvic radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2007 Mar;19(2):162. 
24 Joynson CP, Sundar S, Symonds P. Anaemia is associated with poor overall survival but not with inferior local control in patients with muscle invasive bladder carcinoma treated by radical external beam radiotherapy. A retrospective study. Clin Oncol (R Coll Radiol). 2006 Dec;18(10):728-34. 
25 Sharma R, Sundar S. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8. Eur Urol. 2007 Apr;51(4):1146. Epub 2006 Dec 4. 
26 Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol). 2006 Nov;18(9):702-9. 
27  Khan S, Dhadda A, Fyfe D, Sundar S. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl). 2008 Jan;17(1):19-25.
28 Cox RA, Sundar S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br J Cancer. 2008 Jan 15;98(1):238-9.  (pdf full text copy)
29 Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik EM, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC  trial 22991. Eur J Cancer.2009 Nov;45(16):2825-34.
30 Sundar.S. Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol. 2011 Dec;60(6):e51. Epub 2011 Sep 17
31 Mishra N, Petrovic S, Sundar S. A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy. Med Phys. 2011 Dec;38(12):6528.
32 Perry CJ, Sundar S. Cabazitaxel Rechallenge at Prostate-Specific Antigen Relapse After Previous Cabazitaxel and Docetaxel Chemotherapy: Clin Genitourin Cancer. 2012 Mar 23. (pdf full text copy).
33 Ho JW, Sundar S . Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? . Clin Genitourin Cancer. 2012 Mar;10(1):50-3. Epub 2012 Jan 14.
34 Sundar S, Dickinson PD. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Reports 2012;10.1136/bcr.11.2011.5238 (pdf full text copy)
35 Pascoe AC, Sundar S. Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol. 2012 Mar 22;7(1):43.
36 Dickinson PD, Peel DN, Sundar S. Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. Br J Cancer. 2012 Apr 10;106(8):1464-5. doi: 10.1038/bjc.2012.78. Epub 2012 Mar 13.
37 Sundar S. Sugar-free medicines are counterproductive. Br Dent J. 2012 Sep 7;213(5):207-8. doi: 10.1038/sj.bdj.2012.777.
38 Dickinson P, Sundar S. Salvage radiotherapy after high intensity focused ultrasound for prostate cancer. BMJ Case Reports June 2012 (10.1136/bcr.03.2012.6127).
39 Dickinson, P.D, Chan, S.Y, Sundar, S. The Clinical Usefulness of DNA Aneuploidy in Borderline Ovarian Tumours. Onkologie 2012;35:607 (DOI:10.1159/000343264)
40 Sundar S. The return of the snake oil salesmen: the sequel. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):571. doi: 10.1016/j.ijrobp.2012.06.016
41 Sundar S. Some forms of knowledge are more equal than others. BMJ. 2012 Nov 6;345:e7429. doi: 10.1136/bmj.e7429
42 Adhikaree J, Newby Y, Sundar S.     Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep. 2014 Jan 30;2014. pii: bcr2013202861. doi: 10.1136/bcr-2013-202861.
43 Malik Z, Payne H, Ansari J, Chowdhury S, Butt M, Birtle A, Sundar S, Eswar CV, Hughes S, Bahl A.     Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.AdvTher. 2013 Dec;30(12):1041-66. doi: 10.1007/s12325-013-0070-z. Epub 2013 Nov 26
44 Sundar S.     The law of unintended consequences. J R Soc Med. 2013 Aug;106(8):303. doi: 10.1177/0141076813496235
45 Sundar S. Claims about NHS deficiencies without robust data undermine trust. BMJ. 2013 Oct 15;347:f6158. doi: 10.1136/bmj.f6158
46 Sundar S.     Patients with cancer say yes to palliative chemotherapy. BMJ. 2013 Jul 23;347:f4647. doi: 10.1136/bmj.f4647
47 Silverman R, Smith L, Sundar S.     Benchmarking 30 day mortality after palliative chemotherapy for solid tumours.ClinOncol (R CollRadiol). 2014 Apr;26(4):236. doi: 10.1016/j.clon.2013.12.005. Epub 2014 Jan 15
48 S.Sundar.Saatchi bill”: legal hurdles and clinical irrelevance. BMJ 2014; 348 doi: (Published 14 May 2014).
49 Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR;for the CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol. 2014 May 12. pii: S1470-2045(14)70189-5. doi:10.1016/S1470-2045(14)70189-5
50 O’Cathail M, Sundar S. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.Eur Urol. 2014 Dec 17. pii: S0302-2838(14)01273-1. doi: 10.1016/j.eururo.2014.12.018
51 Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2014 Dec 10. pii: S1470-2045(14)71160-X. doi: 10.1016/S1470-2045(14)71160-X
52 Sundar S, Do J, O’Cathail M. Misconceptions about ‘do-not-resuscitate (DNR)’ orders in the era of social media. Resuscitation. 2014 Oct 30. pii: S0300-9572(14)00798-9. doi:10.1016/j.resuscitation.2014.10.014
53 Sundar S. Milk and mortality: the potential effects of modern milk production. BMJ. 2014 Nov 26;349:g7006. doi: 10.1136/bmj.g7006
54 Sundar S. Clinical surgical trials need to be encouraged. BMJ 2015; 350     doi:
55 Adhikaree J, Newby Y, Sundar S. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju509. doi: 10.1093/jnci/dju509
56 Sundar S. New law on consent will overload seriously ill patients. BMJ. 2015 Apr 7;350:h1787. doi: 10.1136/bmj.h1787
57 A Bahl, S Masson, Z Malik, AJ Birtle, S Sundar, RJ Jones, ND James, MD Mason, S Kumar, D Bottomley, A Lydon, S Chowdhury, J Wylie and JS de Bono. Final Quality of Life and Safety Data for patients with mCRPC treated with Cabazitaxel in the UK Early Access Programme (NCT01254279). BJU Int. 2015 Dec;116(6):880-7. doi: 10.1111/bju.13069
58 Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, Vees H, Zilli T, Ozsahin M . Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):904-10. doi: 10.1016/j.ijrobp.2015.03.019. Epub 2015 Mar 25.
59 Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197
60 Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055
61 Sundar S. Resuscitation is futile in terminally ill patients. BMJ. 2016 Feb 10;352:i598. doi: 10.1136/bmj.i598.
62 James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5.
63 Sundar S, O’Cathail M. Neutrophil-lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer. JRSM Open. 2015 Nov 3;6(12):2054270415611332. doi: 10.1177/2054270415611332.
64 Silverman R, Johnson K, Perry C, Sundar S. Degree of Rectal Distension Seen on Prostate Radiotherapy Planning CT Scan Is Not a Negative Prognostic Factor in the Modern Era of Image-Guided Radiotherapy. Oncology. 2016;90(1):51-6. doi: 10.1159/000441225.
65 Sundar S, Burge F. Geographical tongue induced by axitinib. BMJ Case Rep. 2015 Oct 16;2015. pii: bcr2015211318. doi: 10.1136/bcr-2015-211318.
66 Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, Ralph C.A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. Eur Urol. 2016 Mar;69(3):450-6. doi: 10.1016/j.eururo.2015.08.035.
67 Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S1, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam Sundar, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J Clin Oncol. 2017 Jan;35(1):48-55. Epub 2016 Oct 28.
68 Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T. Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828
69 Silverman R, Taylor S, Walker G, Sundar S. Making it Less Taxing: Reduced Dose Cabazitaxel in Castration-refractory Prostate Cancer. Clin Oncol (R Coll Radiol). 2017 Jun;29(6):394-395. doi: 10.1016/j.clon.2017.01.003.
70 Sivanandan MA, Walker G, Sundar S. Prostate Hypofractionated Radiotherapy Trial Results Need to be Interpreted with Caution due to Undertreatment of the Control Arm in the CHHiP Trial.Clin Oncol (R Coll Radiol). 2016 Dec;28(12):797. doi: 10.1016/j.clon.2016.08.008.
71 Masters BJ, Mandeir J, O’Shaughnessy J, Sundar S. Understanding cardiopulmonary resuscitation. J Pediatr. 2017 Nov;190:291-292. doi: 10.1016/j.jpeds.2017.07.031. PMID: 29144260
72 Price JM, Wolfe T, Shawcroft E, Sundar S. Single-fraction Radiotherapy Should be the Standard of Care for Palliation of Cancer Symptoms in Patients with Limited Life Expectancy. Clin Oncol (R Coll Radiol). 2017 Sep;29(9):635-636. doi: 10.1016/j.clon.2017.05.009. Epub 2017 Jun 19. PMID: 28633969